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RATIONALE: NAA15 (N-alpha-acetyltransferase 15) is a component of the NatA (N-terminal acetyltransferase complex). The 
mechanism by which NAA15 haploinsufficiency causes congenital heart disease remains unknown. To better understand molecular 
processes by which NAA15 haploinsufficiency perturbs cardiac development, we introduced NAA15 variants into human induced 
pluripotent stem cells (iPSCs) and assessed the consequences of these mutations on RNA and protein expression.
OBJECTIVE: We aim to understand the role of NAA15 haploinsufficiency in cardiac development by investigating proteomic 
effects on NatA complex activity and identifying proteins dependent upon a full amount of NAA15.
METHODS AND RESULTS: We introduced heterozygous loss of function, compound heterozygous, and missense residues 
(R276W) in iPSCs using CRISPR/Cas9. Haploinsufficient NAA15 iPSCs differentiate into cardiomyocytes, unlike NAA15-
null iPSCs, presumably due to altered composition of NatA. Mass spectrometry analyses reveal ≈80% of identified iPSC 
NatA targeted proteins displayed partial or complete N-terminal acetylation. Between null and haploinsufficient NAA15 cells, 
N-terminal acetylation levels of 32 and 9 NatA-specific targeted proteins were reduced, respectively. Similar acetylation 
loss in few proteins occurred in NAA15 R276W induced pluripotent stem cells. In addition, steady-state protein levels of 
562 proteins were altered in both null and haploinsufficient NAA15 cells; 18 were ribosomal-associated proteins. At least 4 
proteins were encoded by genes known to cause autosomal dominant congenital heart disease.
CONCLUSIONS: These studies define a set of human proteins that requires a full NAA15 complement for normal synthesis and 
development. A 50% reduction in the amount of NAA15 alters levels of at least 562 proteins and N-terminal acetylation of 
only 9 proteins. One or more modulated proteins are likely responsible for NAA15-haploinsufficiency mediated congenital 
heart disease. Additionally, genetically engineered induced pluripotent stem cells provide a platform for evaluating the 
consequences of amino acid sequence variants of unknown significance on NAA15 function.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
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sequencingof CHD probands and their parents have 
enabled the identification of recurrent damaging variants 
in multiple genes that likely are critical for normal cardiac 
development.3 Functional studies are necessary to fur-
ther define these gene functions and the pathogenetic 
mechanisms of damaging variants. While loss of func-
tion (LoF) variants infer that haploinsufficiency of the 
encoded protein contributes to CHD, the consequence 
of missense variants on protein function are less read-
ily interpreted, often leading to classification of these as 
variants of unknown significance although some may 
contribute to the CHD.2
We previously reported 2 patients with CHD with de 
novo heterozygous LoF variants in NAA15 (N-alpha-
acetyltransferase 15), which encodes a protein subunit 
of the NAT (N-terminal [Nt] acetyltransferase) com-
plex.2–4 In addition to CHD, these patients had extra-car-
diac disorders including neurodevelopmental deficits.2,3 
Prior studies have reported damaging NAA15 variants in 
patients with other congenital malformations and neuro-
developmental abnormalities.5–7
Acetylation of the N-terminus of proteins is a prevalent 
modification that occurs in ≈85% of yeast and human pro-
teins.8,9 The effect of Nt-acetylation on proteins is diverse 
and includes changes to protein stability, complex forma-
tion, protein folding, and aggregation.10 The NatA complex, 
one of 8 NAT types, is essential in most, if not all, eukary-
otes and is responsible for the majority of Nt-acetyla-
tion.10,11 This complex binds the ribosome and was shown 
to acetylate nascent polypeptide chains at specific Nt 
amino acids (Ser-, Thr-, Ala-, Val-, Gly-, and Cys-) after the 
initiating methionine is removed.8,10,12,13 The NatA complex 
is formed by the catalytic subunit NAA10 and the auxiliary 
unit NAA15. HYPK (Huntingtin interacting protein K) is 
a chaperone protein that attaches to the NatA complex 
along with subunit NAA50.14–17 NAA50 also forms part 
of the NatE complex, which displays a distinct substrate 
Nonstandard Abbreviations and Acronyms
CHD congenital heart disease
GFP green fluorescent protein
iPSC induced pluripotent stem cells
iPSC-CMs  induced pluripotent stem cell-derived 
cardiomyocytes





• NAA15 (N-alpha-acetyltransferase 15) is an 866 
amino acid subunit of the NatA (N-terminal acetyl-
transferase), which acetylates the N-terminal residue 
of many eukaryotic proteins.
• Patients with congenital heart disease (CHD) have 
genetic variants in the NAA15 gene predicted to be 
harmful, yet there is limited knowledge of how NAA15 
variants cause CHD.
• Human induced pluripotent stem cells (iPSCs) can 
be used as a human model to study biological conse-
quences of genetic variants that may cause disease.
What New Information Does This Article  
Contribute?
• Exome sequence analysis of 4511 patients with CHD 
identified 20 subjects with rare inherited or de novo 
variants predicted to perturb NAA15, which may be 
responsible for their condition.
• NAA15 haploinsufficiency in iPSCs has little effect 
on the transcriptome. However, a 50% reduction of 
NAA15 protein does lead to impaired cardiomyocyte 
contractility and proteome integrity.
• Expression levels of ribosome-associated proteins and 
4 proteins that encode genes known to cause autoso-
mal dominant CHD are altered in NAA15 haploinsuf-
ficient and deficient iPSCs.
CHD, which affects about 1% of newborns, reflects 
defects in heart development during fetal life. Defin-
ing genetic causes of CHD provides new insights 
into mechanisms of cardiac development that may 
eventually benefit patients with CHD and their fami-
lies. We have used induced pluripotent stem cells to 
model NAA15 haploinsufficiency. In iPSCs, NAA15 
haploinsufficiency and deficiency cause loss of N-ter-
minal acetylation of 9 and 32 proteins. In addition, 
we discovered 562 proteins with altered expression 
levels; 18 proteins are ribosome-associated. Among 
affected proteins, 4 proteins are known CHD genes 
and are likely candidates that require a full comple-
ment of NAA15. We conclude that patients with CHD 
with NAA15 haploinsufficiency likely have altered 
ribosomal activity, which effects steady-state levels 
of proteins essential for early cardiac development. 
Genetically engineered iPSCs can be used as a plat-
form for defining the potential pathogenicity of NAA15 
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specificity compared with NatA.10,18 NAA15 is a subunit of 
both the NatA and NatE complexes, and its role is to posi-
tion the catalytic subunits in close vicinity to the nascent 
polypeptides; in the case of NAA10, it also modulates its 
substrate specificity.10,19–21 Additionally, NAA15 interaction 
with NAA10 and HYPK has been implicated in regulation 
of protein folding and Nt-acetylation fidelity.15,22 Abnormal 
NatA complex function has been previously associated 
with human cancers and neurological disorders.5,23,24 To 
date, the relationship between Nt-acetylation, NAA15, and 
CHD has not been investigated.
We studied human isogenic induced pluripotent stem 
cell (iPSC) lines that were engineered to contain NAA15 
variants identified in patients with CHD and predicted 
to be damaging. We evaluated whether iPSCs with 
NAA15 variants differentiated into cardiomyocytes. By 
assessing both Nt-acetylation and protein levels by mass 
spectrometry (MS), we demonstrate that NAA15 haplo-
insufficiency perturbs normal function of undifferentiated 
iPSCs. We identify proteins that require the full comple-
ment of NAA15 to preserve the integrity of these stem 
cells for cardiac development.
METHODS
Data Availability
All data and materials have been made publicly available. 
Further details are provided in the Major Resources Table 
located in the Data Supplement.
Study Cohort With CHD
CHD subjects (n=4511) were recruited to the Congenital Heart 
Disease Network Study of the Pediatric Cardiac Genomics 
Consortium (CHD GENES: URL: https://www.clinicaltrials.gov; 
Unique identifier: NCT01196182) or the DNA biorepository 
of the Single Ventricle Reconstruction trial after approval from 
Institutional Review Boards as previously described.1,25,26 All sub-
jects or their parents provided informed consent. Clinical diag-
noses, including cardiac and noncardiac congenital anomalies, 
were obtained from review of patient charts and family interview.
CRISPR Gene Editing and Mutation 
Confirmation
Isogenic personal genome project 1 iPSCs were modified 
using CRISPR/Cas9 technology to create NAA15 LoF or mis-
sense mutation cell lines.27 Further details provided in Methods 
in the Data Supplement.
Label-Free Quantitative Shotgun Proteomics 
and Data Analysis
Two independent iPSC lines of both wild type (WT) cells and 
NAA15 mutant cells were grow in 10 cm petri dishes until 
near confluency. iPSCs were detached and using Accutase 
(Millipore) and collected in 15 cm centrifuge tubes. Cells were 
centrifuged (Beckman) in a 15 mL tube at 1000 rpm for 5 
minutes. Cells were washed with PBS and pelleted by centrifu-
gation. Eight samples of each genotype was collected, and a 
total of 24 samples were prepared for LC-MS/MS/ analysis. 
Further details provided in Methods in the Data Supplement.
The MS proteomics data have been deposited to the 
ProteomeXchange Consortium (http://proteomecentral.pro-
teomexchange.org) via the PRIDE partner repository with the 
data set identifiers PXD017672 and PXD018013.
Bioinformatic Analysis and Gene Ontology 
Analysis
Gene ontology annotation proteome was derived using the 
R package clusterProfiler.28 Proteins were classified by Gene 
ontology annotation based on biological process, molecular 
function, and cellular component. Quantified proteins detected 
by MS of iPSCs were used as a background and other param-
eters with default. The P values were adjusted by Bonferroni 
correction for multiple testing.
Statistics
Single comparisons were analyzed by using the Student t test, 
with significance defined as P<0.05. Multiple comparisons 
between genotypes were analyzed using 1-way ANOVA with 
post hoc Tukey HSD, with significance defined as P<0.05. For 
proteomics, pairwise SAM t tests (or pairwise statistical test-
ing using the SAM method29) were performed and significant 
hits determined using as cutoff values a permutation based 
false discovery rate (FDR) of 0.01 (1000 permutations) and 
a background variance parameter s0 of 1. For all experiments 
analyzed for statistical significance, only within-test corrections 
were made.
RESULTS
NAA15 Variants Are Associated With CHD and 
Other Extra Cardiac Anomalies
Whole exome sequencing of 4511 patients with CHD 1,2,4 
identified 4 subjects with a rare LoF variant (allele fre-
quency <0.00005) in the NAA15 gene, resulting in 
NAA15 haploinsufficiency (Figure 1A). Parental analy-
ses indicated that 3 of these LoF variants (p.Ser761*, 
p.Lys336Lys fs*6, and p.Arg470*) arose de novo in the 
probands.2,4 The inheritance of the p.Ala718fs vari-
ant is uncertain, as parental samples were unavailable. 
Among ≈125 000 subjects in the gnomAD database,12 
14 NAA15 LoF variants are reported, inferring an 8.9-
fold higher frequency of NAA15 LoF variants in CHD 
probands (P=0.002).
The CHD phenotypes included tetralogy of Fallot, 
heterotaxy with d-looped ventricles, transposition of the 
great arteries, and hypoplastic left or right heart syn-
drome (Figure 1C and Table I in the Data Supplement). 
In addition to cardiac anomalies, all 4 patients with CHD 
with a NAA15 LoF variant had extracardiac anomalies 
including seizures, neurobehavioral, ophthalmologic, 
auditory, or orthopedic disorders (Figure 1C and Table I 
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We also identified 15 very rare (allele frequency 
<1.0×10−5e-5 or absent from the gnomAD database12) 
inherited NAA15 missense variants among these 4511 
patients with CHD (Figure IA and Table I in the Data Sup-
plement). In addition, one missense variant, R276W (Fig-
ure 1A and Figure IA and IB in the Data Supplement), 
could not be assessed for inheritance. The frequency of 
rare missense alleles in the Pediatric Cardiac Genomics 
Consortium (PCGC) cohort was 0.0035 (n=16 of 4511 
CHD probands), significantly higher than the frequency 
observed among ≈115 000 Gnomad subjects (frequency, 
0.002; n=198; P=0.02; odds ratio, 1.8). CHD probands 
with rare NAA15 missense variants had notably fewer 
extracardiac anomalies than CHD probands with NAA15 
LoF variants (Table I in the Data Supplement). Hence, 
despite the observation that these very rare NAA15 mis-
sense variants were transmitted from an unaffected par-
ent, we suspected that some of them contribute to CHD.
Genetically Engineered iPSCs Model NAA15 
Haploinsufficiency
We introduced NAA15 variants into the iPSC line, per-
sonal genome project 1, using CRISPR/Cas9 gene 
editing (see Methods in the Data Supplement) to create 
human iPSCs with reduced or no NAA15 protein. Two 
independent cell lines were constructed with each geno-
type NAA15−/−, NAA15+/−, and NAA15+/R276W (Figure 1A, 
Figure IA through IC and Table II in the Data Supple-
ment) and studied as detailed below. NAA15 variants in 
iPSCs were confirmed both by Sanger sequencing and 
next generation sequencing of PCR amplified products 
(Figure IIA through IIC in the Data Supplement).
RNA expression levels for each of the 2 independent 
iPSC lines in NAA15+/+ and NAA15-mutant iPSCs, were 
first characterized by RNAseq. NAA15 mRNA levels 
were reduced by 56% and 24% in the NAA15+/− and 
NAA15+/R276W iPSCs, respectively (Figure 2A and Table III 
in the Data Supplement). There was a 99% decrease in 
NAA15 mRNA in NAA15−/− iPSCs, suggesting that these 
variants triggered nonsense-mediated decay (Figure 2A). 
We performed MS-based shotgun proteomics in at least 
3 replicates for each of the 2 independent lines. NAA15 
protein was near-normal levels in NAA15+/− iPSCs but 
absent from NAA15−/− iPSCs (Figure 2B). The amount 
of NAA15 protein detected by MS in NAA15+/− iPSCs 
could represent a proportion of truncated NAA15 poly-
peptides. To confirm this hypothesis, NAA15 protein lev-
els were measured in 2 independent biological replicates 
of both WT and NAA15 mutant iPSCs by Western blot-
ting (Figure IID and IIE in the Data Supplement), which 
supported this conclusion. NAA15 protein was reduced 
Figure 1. NAA15 variants discovered in patients with congenital heart disease patients.
A, Schematic diagram of the NAA15 (N-alpha-acetyltransferase 15) gene. The NAA15 gene consists of tetracopeptide repeats (blue) essential 
for interaction with the NatA (N-terminal acetyltransferase) complex subunit NAA10 and a HYPK (Huntingtin interacting protein K) interacting 
domain at the C terminus. Location of variants identified in patients with congenital heart disease (CHD; loss of function [LoF] variants are 
underlined) and CRISPR/Cas9-derived variants in induced pluripotent stem cell (iPSCs; magenta) are shown. B, The subunit composition of NatA 
and NatE complexes. NAA15 is the auxiliary unit for both complexes. C, Table of cardiovascular and neuronal clinical phenotypes of patients with 
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in NAA15+/− iPSCs by about 50%, and full length NAA15 
protein was not detectable in NAA15−/− iPSCs (Figure IID 
and IIE in the Data Supplement).
Because NAA15 is normally associated with com-
ponents NAA10, HYPK, and NAA5015,17,18 (Figure 1B), 
we assessed the levels of these proteins in the mutant 
iPSCs using MS. Both NAA15−/− and NAA15+/− iPSCs 
showed decreased protein levels of NAA10 (Figure 2B). 
NAA50, the catalytic unit of NatE and binding partner 
of NAA15 protein, was reduced in NAA15−/− iPSCs. Sig-
nificant reduction of the NAA50 protein did not occur 
in NAA15+/− iPSCs (Figure 2B). Noticeably, HYPK, a 
NAA15 binding partner and subunit of the NatA complex 
was significantly reduced in both NAA15+/− and NAA15−/− 
iPSCs (Figure 2B).
We further explored the functional effects of NAA15+/− 
and NAA15+/R276W using a yeast assay in which the hNatA 
(human NatA complex) functionally replaced yeast NatA, 
as shown by complementation of growth phenotypes 
with partial rescue of the NatA-specific Nt-acetylome.8 
HsNatA D335fs and S761* failed to rescue the temper-
ature-sensitive growth phenotype of yNatA∆ (Figure IIIA 
through IIIC in the Data Supplement), suggesting that 
NAA15+/− results in impaired NatA functionality. How-
ever, in this yeast assay, human HsNatA R276W rescued 
yeast growth suggesting at least partial NatA function 
in yeast (Figure IIIC in the Data Supplement). Notice-
ably, Schizosaccharomyces pombe NAA15 has a tryp-
tophan residue at position 276 while all mammals have 
an arginine residue, which suggests that this residue is 
functionally important in human cells. As such, we sug-
gest that rescue of yeast growth experiments might not 
fully provide functional assessments of mutant human 
NAA15 proteins.
Figure 2. NAA15+/− and NAA15+/R276W induced pluripotent stem cells (iPSCs) develop into cardiomyocytes, while NAA15 
(N-alpha-acetyltransferase 15) null iPSCs have reduced viability.
A, Graph shows RNA expression of the NatA (N-terminal acetyltransferase) components in NAA15-mutant iPSCs. NAA15 RNA levels are 
significantly lowered in iPS cells with NAA15+/− and NAA15−/− variants compared with wildtype iPSCs. Data was collected from 2 independent 
cell lines for each genotype and as technical replicates for selected lines. Total cell lines analyzed: NAA15+/+ (n=3), NAA15−/− (n=4), 
NAA15+/− (n=4), and NAA15+/R276W (n=2). Significance of differences between NAA15 mutant iPSCs and wildtype iPSCs were evaluated by 
Student t tests, P<0.05 (P values were adjusted by Bonferroni correction; only significant adjusted P values are displayed). All data points are 
presented and plotted as mean±SEM. B, Graph represents fold change ratios of relative protein levels in NAA15 mutant iPSCs compared 
with wildtype iPSCs for Nat complex subunits. Relative protein abundance was quantified by MaxLFQ algorithms integrated in the MaxQuant 
software. Data was collected from two independent undifferentiated iPS cell lines for each NAA15 mutant genotype and as technical 
replicates for each cell line. Total cell lines analyzed: NAA15+/− (n=8), NAA15−/− (n=8), NAA15+/− (n=7), and NAA15+/R276W (n=8). Significant 
changes indicated by P values were calculated using pairwise comparison SAM t test method and a permutation based false discovery rate 
(FDR) of 0.01 (1000 permutations) as cutoff values with a background variance parameter s0 of 1. All data points are presented and plotted 
as mean±SEM. C, Representative images of NAA15+/+ iPSCs and NAA15+/− iPSCs stained with cardiac troponin T antibody (green), α-actinin 
(magenta), and DAPI for nuclei (blue). A representative image for each cell type is presented. Normal sarcomeres were observed in both 
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NAA15+/− and NAA15+/R276W iPSCs Develop Into 
Contractile Cardiomyocytes, While NAA15−/− 
iPSCs Have Reduced Viability
To test whether NAA15 variants have an effect on iPSC 
maturation, 2 independent iPSC lines for each genotype 
(NAA15−/−, NAA15+/−, and NAA15+/R276W) were differenti-
ated into cardiomyocytes using a 13-day differentiation 
protocol to assess for the development and contractility 
of sarcomeres.30,31 Both NAA15+/− and NAA15+/R276W cells 
differentiated into cardiomyocytes (Figure 2C, a and b), 
however, NAA15−/− iPSCs grew slowly (data not shown) 
and failed to differentiate. Cell viability of NAA15-mutant 
iPSCs was assessed (see Methods in the Data Supple-
ment). Similar to observations reported in NAA15/NatA 
yeast knockout and human knockdown cells,19,23,32–34 
NAA15−/− iPSCs had significantly retarded growth and 
cell death (P=0.001; average cell death is 12% in 
NAA15+/+ iPSCs versus 32% in NAA15−/− iPSCs, n=2). 
NAA15+/− iPSC-derived cardiomyocytes (iPSC-CMs) 
were stained with cardiac troponin T and actinin antibod-
ies to visualize sarcomere structures (Figure 2C, a and b). 
NAA15 mutant cell sarcomeres were indistinguishable 
from WT cell sarcomeres (Figure 2C, a and b and Figure 
IV and Table IV in the Data Supplement).
Contractility of NAA15+/− and NAA15+/R276W iPSC-CMs 
was monitored by live image analysis (Movies I and II in 
the Data Supplement). Two biological replicates of NAA15 
mutant iPSC-CMs and one of 2 biological replicates for 
WT iPSC-CMs were incubated with GFP (green fluo-
rescent protein)-actinin lentivirus to enable high fidelity 
tracking of sarcomere function35(Movies III through V in 
the Data Supplement). The lengths of GFP-labeled sarco-
meres were measured during the contractile cycle. Con-
tractile measurements of unloaded (ie, sarcomeres that 
were not working against resistance) demonstrated no 
difference in rates of sarcomere shortening or contrac-
tion between mutant and WT cells (Figure VA in the Data 
Supplement). To better recapitulate native cardiomyocyte 
architecture and mechanics, the function of loaded sar-
comeres from these cells grown as 3-dimensional micro-
tissue structures,36,37 where sarcomeres work against 
resistance, were created from WT iPSC-CMs and 2 bio-
logical replicates of NAA15 mutant iPSC-CMs (Movies 
VI through VIII in the Data Supplement). In contrast to 
unloaded 2-dimensional tissue sarcomere function, image 
analysis show loaded NAA15+/− iPSC-CM sarcomeres 
exhibited a smaller percent contraction than WT iPSC-CM 
sarcomeres (Figure VB in the Data Supplement).
Nt-acetylation in NAA15 Haploinsufficient, Null, 
and R276W Missense iPSCs
We studied Nt-acetylation of 2 biological replicates in 
iPSCs with NAA15 variants and WT using a MS-based 
Nt enrichment assay.8,38–40 NatA acetylates N-termini 
containing Ser-, Thr-, Ala-, Val-, Gly-, or Cys.10,12 We 
identified a total of 989 previously annotated N-termini41 
in one or both of the 2 independent cell lines for WT 
and NAA15 mutant iPSCs (Table V in the Data Supple-
ment); ≈650 N-termini peptides were identified in each 
cell line (Tables V and VI in the Data Supplement). NatA 
targeted sequences represented ≈60% of the 989 
detected N-termini peptides (Tables V and VI in the Data 
Supplement); no Cys-starting peptides were detected. In 
NAA15+/+ iPSCs, we observed 17 Nt peptides that were 
partially acetylated (10%–95%) and 359 with complete 
(>95%) Nt-acetylation (Figure 3A and Tables V and VI in 
the Data Supplement). Of the completely or partially Nt-
acetylated peptides,8,10 98% have an alanine, threonine, 
or serine at position 2 (Figure 3B and Tables VI and VII 
in the Data Supplement). However, peptides with partial 
acetylation have a much higher fraction of Nt glycine or 
valine residues (Figure 3C and Tables VI and VII in the 
Data Supplement). The preference for acetylation of pro-
teins with Nt alanine and serine residues was preserved 
in NAA15-mutant iPSCs as observed in previous studies 
(Tables VI and VII in the Data Supplement).23
Protein Nt-acetylation in NAA15 mutant iPSCs was 
compared with Nt-acetylation in WT iPSCs. Only a lim-
ited number of putative NatA-type N-termini substrates 
had >10% difference in acetylation between wild type 
and mutant iPSCs (Figure 3, Table 1, and Figure VI in 
the Data Supplement). In NAA15−/− iPSCs 32 proteins 
showed these changes (Figure 3B through 3D and 
Table 1). Notably, all proteins that had partial acetylation 
in WT iPSCs lacked Nt-acetylation in NAA15−/−. Nine of 
these proteins were altered in NAA15+/− iPSCs and 8 
had altered Nt-acetylation in NAA15+/R276W iPSCs (Fig-
ure 3E and 3F, Table 1).
All proteins with reduced acetylation in mutant iPSCs 
displayed NatA-type substrate specificity (Tables 1 and 2, 
Table V in the Data Supplement). Greater than 50% of 
proteins with altered Nt-acetylation had an alanine residue 
at position 2 and >30% also had an alanine residue at 
position 3 (Table 2).23 The distribution of N-terminal resi-
dues in proteins with altered Nt-acetylation did not differ 
significantly from the distribution of N-terminal residues in 
proteins with unchanged N-terminal acetylation in these 
cells (not shown). We deduced that NAA15 variants or 
deficiency altered N-terminal acetylation in a small num-
ber of NatA substrate proteins and with no preference for 
an extended N-terminal amino acid substrate specificity.
We noticed that some proteins reduced in Nt-acetyla-
tion (Figure 3D) have functions in cellular proliferation and 
survival,42–46 perhaps accounting for the deficits in growth 
and viability of NAA15−/− iPSC.41–46 To understand whether 
the change in Nt-acetylation status compromised the func-
tion of these proteins and contributed to the phenotype 
of NAA15−/− iPSCs, we used a combination of shotgun 
MS-based proteomics and pairwise comparison by SAM t 
test (FDR=0.01; Tables VIII through X in the Data Supple-
ment). Nine proteins with reduced acetylation correlated 
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(Figure 3D and 4A). Among these, measurable acetylation 
occurred in 3 proteins in NAA15+/− and in one protein in 
NAA15+/R276W iPSCs (Figure 3E and 3F).
Altered Protein Expression Due to NAA15 
Haploinsufficiency or Deficiency
Using shotgun proteomics, we studied 2 independent 
undifferentiated iPSC lines for each NAA15 mutant 
genotype and at least 3 technical replicates for each 
sample to assess protein levels (Table VIII in the Data 
Supplement). Among 5196 proteins identified by MS, 
extracts from NAA15+/- iPSCs, NAA15-/- iPSCs, or 
both revealed a total of 1209 proteins that were dif-
ferentially expressed (pairwise comparison by t test) 
compared with WT iPSCs (Figure 4A and 4B, Figure 
VII and Tables VIII through X in the Data Supplement). 
Five hundred sixty-two proteins were differentially 
Figure 3. N-terminal acetylation in NAA15+/− and NAA15−/− induced pluripotent stem cells (iPSCs).
A, N-terminal peptides acetylated in NAA15+/+ iPSCs are categorized by NAT-type substrate specificity. NatA (N-terminal acetyltransferase) 
targets are displayed according to percent Nt-acetylation; Nt-acetylation >10% highlighted in gold and Nt-acetylation <10% highlighted in 
light gold. B and C, The number of Nt-acetylated NatA-type N-terminal peptides represented by residues A, G, S, T, or V in NAA15 mutant and 
wildtype iPSCs. Data is displayed as the absolute number of peptides measured from the sum of 2 biological replicates for each genotype. 
Alanine and serine residues are preferentially acetylated in peptides with >10% Nt-acetylation; glycine and valine residues are representative of 
N-termini with <10% Nt-acetylation. Primary peptide summary provided in Table V in the Data Supplement. There were no statistically significant 
differences between genotypes (hypergeometric test; data not shown). D–F, Representative scatter plots display the correlation of the degrees 
of Nt-acetylation of all N-termini identified as NatA targets in NAA15−/−, NAA15+/−, NAA15+/R276W, and NAA15+/+ iPSCs. Each plot compares 
NAA15 (N-alpha-acetyltransferase 15) mutant iPSCs to wildtype iPSCs. Differentially acetylated N-termini are found below the line of identity (y 
intercept=0, slope=1). Peptides lose acetylation moieties in NAA15-mutant iPSCs. NAA15−/− iPSCs have the largest number of peptides (n=32) 
with reduced Nt-acetylation. There are N-termini with reduced N-terminal acetylation in NAA15+/− iPSCs (n=9) and NAA15+/R276W iPSCs (n=8). 
Decreased protein expression changes are highlighted in red. COPS3 indicates COP9 signalosome complex subunit 3; DDX54, ATP-dependent 
RNA helicase; NDUFB6, NADH dehydrogenase (ubiquinone) 1β subcomplex subunit 6; PABPN1, polyadenylate-binding protein 2; PPWD1, 
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expressed in both NAA15+/− and NAA15−/− iPSCs com-
pared with WT iPSCs and 505 proteins in NAA15−/− 
iPSCs but not NAA15+/− iPSCs (Figure 4B, Figure VII 
and Tables VIII through X in the Data Supplement). 
More than 60% of differentially expressed proteins 
had a NatA-target residue at position 2 of the mature 
protein (Table XI in the Data Supplement). NatA-target 
residues, alanine and serine, were frequently observed 
at position 2. Similar frequencies are seen in proteins 
with no expression changes (Table XI in the Data 
Table 1. Proteins With Altered N-Terminal Acetylation in Wildtype and NAA15 Mutant iPSCs*
Accession Description
Nt-acetylation percentage Protein levels (fold change)
+/+ +/- -/- +/R276W +/- / +/+ -/- / +/+
Q9UNS2 COPS3 99.4 99.9 83.6 99.6 1.87 2.00
Q8TDD1 ATP-dependent RNA helicase (DDX54) 30.8 0 0.7 29.6 2.00 2.46
O60869 EDF1 93 81.6 99 97.5 0.38 0.31
Q9NZM5 Ribosome biogenesis protein (NOP53) 70.6 0 0 84 2.83 4.92
P16401 Histone H1.5 96.7 92.8 37.1 98.2 0.20 0.22
P16403 Histone H1.2 99.5 98.4 50.6 99.5 0.27 0.29
P16402 Histone H1.3 99.6 99.5 62 99.6 0.27 0.29
P10412 Histone H1.4 97.6 93.7 30.9 98.4 0.27 0.29
O95139 NDUFB6 57.5 0 7.4 0 0.33 0.27
Q86U42 PABPN1 99.8 99.3 67.6 0 2.30 2.30
Q15102 PAFAH1B3 99.7 99.6 84.7 99.4 3.48 4.29
Q96BP3 PPWD1 99.8 0 85.6 98.8 0.33 0.13
Q9UN37 VPS4A 98.6 98.6 79.4 99.4 1.00 0.27
Q9HB71 CACYBP 99.4 99.6 67.9 100 .81 .93
P14854 COX6B1 99.2 99.2 67.3 99.2 1.62 1.62
Q02790 FKBP4 14.3 11.9 3.3 14.3 0.81 3.43
Q92616 eIF-2-α kinase activator GCN1 62 54.2 7.3 0 1.41 1.15
O76003 GLRX3 98.2 0 85.3 94 1.15 1.07
Q00839 HNRNPU 99 98.7 79.9 96.4 1.52 1.62
Q8IXQ5 KLHL7 96.5 94 48.7 98.3 0.76 0.81
Q96AG4 LRRC59 60 52.3 7.9 70.7 1.41 1.62
P62937 PPIA 34.3 31.7 6.4 29 1.15 0.93
P62913 RPL11 99.6 99.3 77.9 99.6 1.00 0.93
P40429 RPL13A 95.4 92 3.5 95.3 0.76 0.76
P25398 RPS12 98 99 82.4 92.9 1.23 1.23
Q8NI27 THOC2 99.7 50.4 0 0 1.00 1.07
Q9Y5J9 TIMM8B 95.5 96 82.7 0 1.62 1.52
O94826 TOMM70A 98.7 98 61 98.4 1.41 1.62
Q04323 UBXN1 99.1 96.7 41 99.3 0.81 0.81
P31946 YWHAB 95.3 93.7 50.9 96.6 1.32 1.41
Q9NXW9 ALKBH4 97.5 44.6 0 0 ND† ND†
Q9NRG0 CHRC1 99.4 88.3 99.7 99.1 ND† ND†
Q9Y241 HIG1A 98.9 99.4 87.3 99.3 ND† ND†
P17096 HMGA1 99.5 99.5 88.8 99.6 ND† ND†
ALKBH4 indicates α-ketoglutarate-dependent dioxygenase; CACYBP, calcyclin-binding protein; CHRC1, chromatin accessibility complex protein 1; COPS3, COP9 
signalosome complex subunit 3; COX6B1, cytochrome c oxidase subunit 6B1; EDF1, endothelial differentiation-related factor 1; FKBP4, peptidyl-prolyl cis-trans isom-
erase; GLRX3, glutaredoxin 3; HIG1A, HIG1 domain family member 1A, mitochondrial; HMGA1, high mobility group protein HMG-I/HMG-Y; HNRNPU, heterogeneous 
nuclear ribonucleoprotein U; iPSC, induced pluripotent stem cell; KLHL7, Kelch-like protein 7; LRRC59, leucine-rich repeat-containing protein 59; NDUFB6, NADH 
dehydrogenase (ubiquinone) 1β subcomplex subunit 6; PABPN1, polyadenylate-binding protein 2; PAFAH1B3, platelet-activating factor acetylhydrolase IB subunit 
γ; PPIA, peptidyl-prolyl cis-trans isomerase A; PPWD1, peptidyl-prolyl isomerase domain and WD repeat-containing protein 1; RPL11, 60S ribosomal protein L11; 
RPL13A, 60S ribosomal protein L13a; RPS12, 40S ribosomal protein S12; THOC2, THO complex subunit 2; TIMM8B, mitochondrial import inner membrane translo-
case subunit; TOMM70A, mitochondrial import receptor subunit; UBXN1, UBX domain-containing protein 1; VPS4A, vacuolar protein sorting-associated protein 4; and 
YWHAB, 14-3-3 protein beta/alpha.
*Altered acetylation levels= >10% deviation.
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Supplement). Despite the large numbers of differen-
tially expressed proteins, there were very few, if any, 
significant differences in mRNA levels, as assessed 
by RNAseq analysis (Tables III and IV in the Data 
Supplement).
Among differentially expressed proteins identified 
in NAA15+/− iPSCs and NAA15−/− iPSCs, the levels of 
HYPK, a component of the NatA complex that interacts 
with NAA15, were significantly reduced (Figure 1C).14–
17,22 A total of 29 out of 54 known interactors of HYPK 
were detected in the WT iPSCs.47 Although HYPK was 
decreased in MS measurements, there was no enrich-
ment of HYPK interacting proteins that were differentially 
expressed. Only 6 of 29 known HYPK interacting pro-
teins were decreased in NAA15-mutant iPSCs (P=0.3; 
Tables IX and X in the Data Supplement).
To test the hypothesis that differentially expressed 
proteins shared a common function, the 562 proteins 
differentially expressed in both NAA15+/− and NAA15−/− 
iPSCs were analyzed by gene ontology analysis using 
clusterProfiler (implemented in R; Methods in the Data 
Supplement).28 Of the 3 gene ontology enrichment pro-
cesses that were performed, we found no enrichment 
after Bonferroni correction for proteins with shared bio-
logical function or molecular processes; however, 41 
ribosomal (-associated) proteins with altered expres-
sion levels were observed (P=5×10−6), Table XII in the 
Data Supplement, Figure 4C). These proteins included 
the catalytic subunit of the NatA complex, NAA10, and 
ribosomal proteins of the 60S large and 40S small 
ribosome subunits that function in protein synthesis 
(Figure 1B, Table XII in the Data Supplement, and Fig-
ure 4D and 4E).48–52
Ribosomal Protein Deficiency Due to NAA15 
Haploinsufficiency
Twenty-nine ribosomal proteins of the 84 proteins 
that comprise 60S or 40S ribosomal subunit53,54 were 
affected in NAA15+/− and NAA15−/− iPSCs; eleven 60S 
large ribosomal proteins and 6 small ribosomal proteins 
were affected in both NAA15+/− and NAA15−/− iPSCs 
(Tables IX and X in the Data Supplement, Figure 4D). 
Twelve ribosomal proteins were differentially expressed 
in NAA15−/− iPSCs but not in NAA15+/− iPSCs (Tables IX 
and X in the Data Supplement).
NAA15 facilitates binding of the NatA complex to 
the ribosome.55–58The general docking site for NatA 
resides at the ribosomal exit tunnel near large ribo-
somal unit RPL25 (L23A), a general docking platform 
for various factors that are transiently associated with 
ribosomes.55,57,59–61 Dysregulated ribosomal proteins 
observed in both NAA15+/− and NAA15−/− iPSCs clus-
tered near the NatA docking site (Figure 5A through 
5C). Affected small ribosomal subunits (RPS18, RPS25, 
RPS16, RPS19, RPS20) were clustered at the head of 
the small ribosomal subunit53 (Figure 5C). Large ribo-
somal units53 (RPL5 [ribosomal protein L5], RPL13, 
RPL15, RPL19, RPL30, RPL31, RPL35, RPL23A, 
RPL39) with low protein levels were clustered at the exit 
tunnel of the ribosome near the NAA15/NatA docking 
site (Figure 5B).
Fetal Heart Expression and Association 
With CHD of Proteins Perturbed in NAA15-
Haploinsufficient iPSCs
Because extensive protein expression studies of human 
and mouse fetal heart are not available, we assessed 
expression of the RNAs encoding these proteins in the 
mouse and human fetal heart62; ≈50% of the 562 pro-
teins are expressed in the mouse and human fetal heart 
(unpublished). Of these 562 proteins, 4 (DHCR7 [7-dehy-
drocholesterol reductase], MAP2K2 [mitogen-activated 
protein kinase kinase 2], NSD1 [nuclear receptor binding 
SET domain protein 1], and RPL5; Table XIII in the Data 
Supplement) are encoded by genes known to cause 
autosomal dominant CHD (Table XIII in the Data Supple-
ment). RNA encoding all 4 of these proteins are found in 
multiple cell types in the human fetal heart (Figure VIII in 
the Data Supplement).
DISCUSSION
Exome sequence analyses of 4511 CHD subjects with 
extra-cardiac phenotypes identified 20 subjects with rare 
Table 2. Second and Third Amino Acid Identities of Peptides 




AA 10 6 5
AD 0 1 0
AE 5 1 1
AQ 2 0 1
AS 2 0 0
SE 5 0 0
SG 1 0 0
SS 1 0 0
ST 1 0 0
TA 1 0 0
TG 1 1 1
TK 1 0 1
TM 1 0 0
TT 1 0 0
VN 1 0 0
A indicates alanine; D, aspartic acid; E, glutamic acid; G, glycine; iPSC, induced 
pluripotent stem cell; K, lysine; M, methionine; N, asparagine, Q, glutamine; S, 
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inherited or de novo variants that are predicted to perturb 
NAA15 (Table I and Figure I in the Data Supplement, 
Figure 1A). Similar NAA15 variants occur in patients 
with neurological abnormalites.5,7 We explored the con-
sequences of NAA15 variants using human iPSCs by 
both transcriptome (RNAseq) and proteomic analyses 
(Figure 2; Figure II and Tables III, IV, VIII, IX, and X in the 
Data Supplement). NAA15+/− cells had ≈50% of normal 
levels but like NAA15+/R276W iPSCs, these differentiated 
into cardiomyocytes. NAA15+/− iPSC-CMs displayed 
normal unloaded contractility, but impaired contractility 
when loaded (ie, working against resistance; Figure V 
in the Data Supplement). NAA15−/− iPSCs produced no 
NAA15 and like yeast cells lacking NAA15, grew slowly 
(Figure 2D).19 NAA15-deficiency had minimal effect on 
the transcriptome but significantly altered the proteome 
consistent with its role in protein modification.
Because NAA15 is a component of the NatA com-
plex, we assessed the level of N-terminal protein acety-
lation in iPSCs carrying NAA15 variants using positional 
proteomics. Approximately 650 proteins with N-termi-
nal sequences that were predicted to be NatA targets 
could be assessed. Only 32 and 9 proteins had altered 
Nt-acetylation in NAA15 null and haploinsufficient cells, 
respectively. By contrast, levels of 562 proteins were 
altered in both NAA15-null and NAA15-haploinsufficient 
cells suggesting a possible role for NAA15 and NatA in 
translation efficiency and protein stability in addition to 
Nt-acetylation. If NAA15 was the only available ribosome 
anchor for NAA10 and the NatA complex in human cells 
as it is in yeast cells,8,55,58 NAA15 null cells should present 
with a complete lack of Nt-acetylation of all NatA sub-
strates. The explanation for the partial effect observed 
may be due to the presence of the NAA15 paralogue 
NAA16 in human cells; however, the low expression of 
NAA16 in iPSCs suggests the need for additional stud-
ies to measure whether the paralogue to NAA15 had any 
effect on N-terminal acetylation. It has been reported that 
NAA16-NAA10 complexes may perform NatA-type Nt-
acetylation in human cells and partially act as a backup 
system for the NAA15-NAA10 NatA complex.63
The levels of 18 of the 81 identified ribosomal pro-
teins were altered in NAA15-haploinsufficent cells. 
NAA15 anchors the NatA complex to the ribosomal 
large subunit via RPL25 (L23A).55–58,64 Consistent with 
this model, some of these affected proteins clustered 
Figure 4. Proteins differentially expressed in NAA15+/− and NAA15−/− induced pluripotent stem cells (iPSCs).
A, Scatterplot displays log2 fold changes of differentially expressed proteins in NAA15+/− and NAA15−/− iPSCs compared with wildtype (WT) 
iPSCs. Approximately 1200 proteins are differentially expressed, 9 and 3 proteins of which have reduced Nt-acetylation in NAA15−/− iPSCs and 
NAA15+/− iPSCs, respectively. Data was collected from 2 independent undifferentiated iPS cell lines for each NAA15 (N-alpha-acetyltransferase 
15) mutant genotype and at least 3 technical replicates for each sample. B, Comparison of differentially expressed proteins in NAA15−/− and 
NAA15+/− iPSCs. Differential expression was considered for log2 fold change |1|. Identified proteins: 5196, quantified proteins: 3911 proteins 
detected by mass spectrometry (C) gene ontology (GO) enrichment of differentially expressed proteins in both NAA15−/− and NAA15+/− iPSCs. 
A total of 41 proteins are localized to the ribosome. Raw P value presented in data table. D, Bar graph represents log2 fold change of ribosomal 














Ward et al NAA15 Haploinsufficiency and CHD
1166  April 16, 2021 Circulation Research. 2021;128:1156–1169. DOI: 10.1161/CIRCRESAHA.120.316966
near the NAA15/NatA docking site. Presumably, NAA15 
binding to one or more of these proteins56 protects them 
from subsequent degradation either during ribosome 
assembly or subsequent ribosomal activity. Previous 
studies have demonstrated that ribosomal subunit defi-
ciency leads to a variety of pathological states.48,50,51,65 
Damaging human variants in ribosomal subunits RPS19, 
RPL5,4 and RPL35A have been identified in patients 
with CHD4 (PCGC consortium data not shown) and also 
contribute to Diamond-Blackfan anemia,50,66,67 a disorder 
that is accompanied by CHD in 30% of patients.68
Among differentially expressed proteins in NAA15 
haploinsufficient cells, 4 (DHCR7, MAP2K2, NSD1, and 
RPL5) are encoded by known CHD genes (Table XIII 
and Figure VIII in the Data Supplement) and are most 
likely responsible for NAA15-haploinsufficient mediated 
CHD.4,69–71 As the precise mechanisms by which each 
haploinsufficiency of each of these genes is defined, we 
anticipate the mechanism(s) will be shared by NAA15 
haploinsufficient patients.
Exome analyses of CHD probands also identified 
16 NAA15 missense variants, including R276W, a vari-
ant of uncertain significance. iPSCs carrying the NAA15 
R276W variant had eight proteins with altered Nt-acet-
ylation, of which 4 had altered Nt-acetylation in NAA15-
haploinsufficient cells. These data suggest that the 
Figure 5. Ribosomal proteins of the 40S small and 60S large subunits affected in NAA15 (N-alpha-acetyltransferase 
15)-mutant iPSCs.
A, Graphical representation of the human 80S ribosomes with affected 40S small and 60S large subunits in both NAA15−/− and NAA15+/− 
iPSCs. Ribosomal proteins down in expression highlighted in dark blue (log2 fold change <−2) and light blue (−2< log2 fold change >−1). NatA 
(N-terminal acetyltransferase) Docking site is highlighted in yellow. B, Diagram showing location of affected 60S large subunits and (C) 40S small 
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R276W variant likely impairs NAA15 function, and con-
sequently NatA function, and like heterozygous LoF vari-
ants contributes to CHD. Future studies of protein levels 
in genetically engineered iPSCs carrying other NAA15 
variants found in CHD probands, will help identify those 
variants contributing to cardiac abnormalities and those 
variants that are likely benign.
In this study, we use genetically engineered iPSC 
models to recapitulate NAA15 LoF and missense variants 
discovered in CHD patients. We observe that variants in 
NAA15 causing NAA15 haploinsufficiency or deficiency 
result in either a reduction or complete depletion of 
NAA15 and NatA protein levels. We find that aberrant 
protein expression of NAA15 alters Nt-acetylation of a 
small number of proteins. Most importantly, a reduction 
of the NAA15 protein interrupts its interaction with the 
ribosome. The failed interaction causes ribosomal defi-
ciency and mis-expression of a large number of pro-
teins most likely involved in heart development. Protein 
expression changes are possibly due to obstructed ribo-
somal machinery and defects in protein synthesis. One 
or more proteins affected in both NAA15-mutant iPSCs 
have been documented as a cause of congenital heart 
defects and are likely candidates required for normal car-
diac developmental processes.
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